Study type

Study topic

Human medicinal product
DiseaseĀ /health condition

Study type

Non-interventional study

Scope of the study

Assessment of risk minimisation measure implementation or effectiveness
Effectiveness study (incl. comparative)

Data collection methods

Secondary use of data
Non-interventional study

Non-interventional study design

Cohort
Study drug and medical condition

Anatomical Therapeutic Chemical (ATC) code

(B01A) ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS

Medical condition to be studied

Atrial fibrillation
Population studied

Short description of the study population

Patients with non-valvular atrial fibrillation at risk for stroke

Age groups

Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Special population of interest

Other

Special population of interest, other

Patients with atrial fibrillation

Estimated number of subjects

9000
Study design details

Main study objective

Quantify associations between anticoagulant choice (warfarin and dabigatran) and the occurrence of selected outcomes in patients with non-valvular atrial fibrillation at risk for stroke.

Outcomes

StrokeMajor bleeding, Stroke or systemic embolismSystemic embolismIschemic strokeHemorrhagic strokeStroke uncertain classificationMajor intracranial bleeding Major extracranial bleedingMajor GI bleedingMajor upper GI bleedingMajor lower GI bleedingMajor urogenital bleedingMajor other bleedingTransient ischemic attackMyocardial infarctionVenous thromboembolismDVTPulmonary embolism

Data analysis plan

After identifying initiators of warfarin or dabigatran with an existing diagnosis of non-valvular atrial fibrillation and at risk for stroke in a large US commercial claims database we will use propensity score methods and time-to-event analyses to estimate the ratio in hazard rates for each of the outcomes of interest.
Documents
Study report
English (211.34 KB - PDF)View document